The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of extended-infusion piperacillin-tazobactam in children hospitalized in …

Piperacillin-tazobactam (TZP) is frequently used to treat severe hospital-acquired infections
in children. We performed a single-center, pharmacokinetic (PK) trial of TZP in children …

Objectives: To characterize the population pharmacokinetics of piperacillin and tazobactam
in critically ill infants and children, in order to develop an evidence-based dosing regimen …

Methods: Blood samples (2–4 per child) were collected from 13 children ages 9 months to 6
years admitted to the pediatric intensive care unit who were receiving standard piperacillin …

Piperacillin/tazobactam, an intravenous antibacterial combination product, has recently
been approved for paediatric (age 2 months to 17 years) use in the USA. The purpose of this …

While extended infusions of piperacillin-tazobactam (TZP) are increasingly used in practice,
the effect of infusion on the pharmacokinetic (PK) profile of TZP has not been widely …

Objectives To develop population pharmacokinetic (PK) models for piperacillin/tazobactam
in neonates and infants of less than 2 months of age in order to determine the appropriate …

Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly
prescribed in the intensive care unit setting. Admitted patients often show large variability in …

The pharmacokinetics of piperacillin and tazobactam were assessed after single-dose
administration to 47 infants and children. Study subjects ranging in age from 2 months to 12 …

The objectives of this study were (i) to compare the plasma concentration–time profiles for
first-dose and steady-state piperacillin administered by intermittent or continuous dosing to …